Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report sent to investors on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Price Performance

Shares of NASDAQ GLMD opened at $15.10 on Friday. The company has a market capitalization of $76.18 million, a price-to-earnings ratio of -6.29 and a beta of 0.67. The business has a 50-day moving average of $3.83 and a 200-day moving average of $4.12. Galmed Pharmaceuticals has a 1-year low of $2.73 and a 1-year high of $23.80.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.